By Fineline Cube 
China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEX) through the introduction method.
Privatization and Merger
The listing follows Sunshine Lake Pharma’s privatization proposal to absorb and merge YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG: 1558) via a share swap arrangement. Under the terms of the agreement, Sunshine Lake Pharma will issue new H shares to all swap shareholders as consideration.
Listing Details
Subject to HKEX approval, the new H shares are expected to be distributed on August 6, 2025, with trading commencing on August 7, 2025. Upon completion of the merger, YiChang HEC will be delisted from HKEX, and its shareholders will become shareholders of Sunshine Lake Pharma.
Company Overview
Sunshine Lake Pharma is an integrated pharmaceutical company focusing on infectious diseases, chronic conditions, and oncology. Its portfolio includes 48 marketed drugs in China and 23 marketed drugs overseas. The company reported revenues of RMB 4.019 billion (USD 561 million) last year.-Fineline Info & Tech